TY - JOUR
T1 - Multimodal imaging of gliomas in the context of evolving cellular and molecular therapies
AU - Keunen, Olivier
AU - Taxt, Torfinn
AU - Grüner, Renate
AU - Lund-Johansen, Morten
AU - Tonn, Joerg Christian
AU - Pavlin, Tina
AU - Bjerkvig, Rolf
AU - Niclou, Simone P.
AU - Thorsen, Frits
N1 - Funding Information:
This work was funded by the Centre de Recherche Public de la Santé (CRP-Santé) of Luxembourg, the University of Bergen and the Haukeland Hospital of Bergen, Norway.
Publisher Copyright:
© 2014 Elsevier B.V.
PY - 2014
Y1 - 2014
N2 - The vast majority of malignant gliomas relapse after surgery and standard radio-chemotherapy. Novel molecular and cellular therapies are thus being developed, targeting specific aspects of tumor growth. While histopathology remains the gold standard for tumor classification, neuroimaging has over the years taken a central role in the diagnosis and treatment follow up of brain tumors. It is used to detect and localize lesions, define the target area for biopsies, plan surgical and radiation interventions and assess tumor progression and treatment outcome. In recent years the application of novel drugs including anti-angiogenic agents that affect the tumor vasculature, has drastically modulated the outcome of brain tumor imaging. To properly evaluate the effects of emerging experimental therapies and successfully support treatment decisions, neuroimaging will have to evolve. Multi-modal imaging systems with existing and new contrast agents, molecular tracers, technological advances and advanced data analysis can all contribute to the establishment of disease relevant biomarkers that will improve disease management and patient care. In this review, we address the challenges of glioma imaging in the context of novel molecular and cellular therapies, and take a prospective look at emerging experimental and pre-clinical imaging techniques that bear the promise of meeting these challenges.
AB - The vast majority of malignant gliomas relapse after surgery and standard radio-chemotherapy. Novel molecular and cellular therapies are thus being developed, targeting specific aspects of tumor growth. While histopathology remains the gold standard for tumor classification, neuroimaging has over the years taken a central role in the diagnosis and treatment follow up of brain tumors. It is used to detect and localize lesions, define the target area for biopsies, plan surgical and radiation interventions and assess tumor progression and treatment outcome. In recent years the application of novel drugs including anti-angiogenic agents that affect the tumor vasculature, has drastically modulated the outcome of brain tumor imaging. To properly evaluate the effects of emerging experimental therapies and successfully support treatment decisions, neuroimaging will have to evolve. Multi-modal imaging systems with existing and new contrast agents, molecular tracers, technological advances and advanced data analysis can all contribute to the establishment of disease relevant biomarkers that will improve disease management and patient care. In this review, we address the challenges of glioma imaging in the context of novel molecular and cellular therapies, and take a prospective look at emerging experimental and pre-clinical imaging techniques that bear the promise of meeting these challenges.
KW - Brain tumors
KW - Computer vision
KW - Image analysis
KW - Magnetic resonance imaging
KW - Molecular imaging
KW - Neuroimaging
KW - Positron emission tomography
KW - Radiology information systems
UR - http://www.scopus.com/inward/record.url?scp=84928206954&partnerID=8YFLogxK
U2 - 10.1016/j.addr.2014.07.010
DO - 10.1016/j.addr.2014.07.010
M3 - Review article
C2 - 25078721
AN - SCOPUS:84928206954
SN - 0169-409X
VL - 76
SP - 98
EP - 115
JO - Advanced Drug Delivery Reviews
JF - Advanced Drug Delivery Reviews
IS - 1
ER -